Research and Markets (http://www.researchandmarkets.com/research/6e95f7/alzheimers_diseas)
has announced the addition of GlobalData's new report "Alzheimer's
Disease - Drug Pipeline Analysis and Market Forecasts to 2015" to
their offering.
Alzheimer's Disease - Drug Pipeline Analysis and Market Forecasts to
2015 is an essential source of information and analysis on the global
Alzheimer's disease market. The report identifies the key trends shaping
and driving the dynamism in the global Alzheimer's disease market. The
report also provides insight on the prevalent competitive landscape and
the emerging players expected to bring significant shifts in the market
positioning of the existing market leaders. Most importantly, the report
provides valuable insight on the pipeline products within the global
Alzheimer's disease sector.
Alzheimer's Disease Market is Forecast to Show Slow Growth until 2015
The analysis shows that the global Alzheimer's disease (AD) market was
valued at $5.4 billion in 2008 and is further being driven up by the
ageing population. The market is expected to grow to $6.2 billion with a
CAGR of 1.8% by the year 2015. Though Eisai/Pfizer's lead product
Aricept will be facing generic competition, life cycle management
programs such as sustained release and transdermal patch formulations
will compensate the revenues of Eisai and Pfizer. The market structure
is projected to change in the near future following the patent expiry of
many of the leading drugs in next 2-3 years. Also, Namenda's (Forest)
patent is set to expire in April 2010. The company has applied for
patent term restoration which, if granted, will extend Namenda's patent
protection until September 2013. Novartis's Exelon is set to expire by
2012. Due to the patent expiry of Aricept and Namenda, sales of Exelon
will be affected. The pipeline for Alzheimer's disease is quite strong
with disease modifying mechanisms. These products, if approved, will
change the entire market scenario by 2015.
Current Market Unsuccessful in Meeting Patient Expectations
The report finds that current competition is weak and the marketed
products are unsuccessful in meeting the needs of the patient, leaving
behind a large segment of unmet need. Current products in the market do
not serve the unmet need of curing the disease. The market continues to
present opportunities for stronger pipeline candidates. The current
drugs are majorly attributed to the symptomatic relief of the current
treatment options rather than the cure itself. The current market is
mainly driven by acetylcholinesterase inhibitors and NMDA antagonists.
This underexploited market holds significant market potential for any
new entrants with disease modifying capability. Designing disease
modifying drugs rather than drugs for providing symptomatic relief is
one of key challenges for this market and could provide a significant
opportunity for any company.
Scope
The scope of the report includes: